Safety of racotumomab in the treatment of patients with non-small cell lung cancer

Article

Abstract: In Cuba, lung cancer ranks second in incidence and first in mortality. Therefore, it is necessary to

Palabras claves:

Adverse events, Clinical trial, Non-small cell lung cancer, Racotumomab

Autores:

Carmen Elena Viada, Estevez D., Gastón Y., Macías A.E., Pérez Ruiz L.

Fuentes:

scopus